Highly pure, multi-epitopic lipopeptide vaccine
delivery system: Synthesis and investigation by Moyle, Peter M.
Highly Pure, Multi-Epitopic Lipopeptide Vaccine 
Delivery System: Synthesis and Investigation
Peter M Moyle,a Colleen Olive,b Aniko Horváth,a Levente Karpati,a
Mei-Fong Ho,b Melinda Burgess,b Michael F Good,b Istvan Totha,*
a School of Pharmacy and School of Molecular and Microbial Sciences (SMMS), 
the University of Queensland, St Lucia 4072, QLD, AUSTRALIA




















e.g. DNA vaccines, virus like particles (VLPs), peptide vaccines






• Disease prevention • Reduces health care costs • Reduces lost work time due to sickness
Introduction
Subunit Vaccines
Contain the minimal microbial components necessary to stimulate 
an appropriate immune response
Advantage
• Vaccines are administered to healthy individuals (normally children).
• These people are being asked to take a medication when they are well.
• Therefore adverse effects must be minimal.
• Removing unnecessary components, reduces the risk of auto-immune diseases and adverse effects.
• Not infectious; No reversion to virulence.
• Can customise the vaccine components to tailor an appropriate immune response.
Problem
• Removing unnecessary components often removes danger signals.
• Need strong adjuvant (‘immune stimulating agent’).
• In the case of peptides:
• Small molecular weight limits their capacity to elicit immune responses.
• Peptides lack the T-helper epitopes required for efficacy in an outbred population.
Carrier
Molecule
































































































1. Synthesize LCP Lipid Core
• Using stepwise solid-phase peptide synthesis


































































































































• Cleave using hydrogen fluoride





































J8:           QAEDK VKQSR EAKKQ VEKAL KQLED KVQ (28mer)
88/30:      DNGKA IYERA RERAL QELGP C (21mer)
Minutes



















































LCP-J8-8830  pure 0-100BIPA 30min C4vyn 214nm 1mlmin
LCP-J8-8830  pure 0-100BIPA 30min C4vyn 214nm 1mlmin
Retention Time
A/ 0.1% TFA/H2O
B/ 90% IPA/0.1% TFA/H2O
Gradient: 0-100%B over 30min
Flowrate: 1mL/min
Detection: 214nm





B10.BR (H-2K) mice (n=10) 4-6 week old female
Prime: 30µg LCP-88/30-J8 either 1:1 in CFA or in 50µL PBS
Boost: 3µg in PBS, days 21, 28, 35, 42, & 49
Intra-peritoneal Challenge
400µL (1 × 105 CFU/mL 88/30 GAS)
Subcutaneous ImmunizationSystemic IgG Antibody Titers (ELISA)
*, P 0.0001; **, P 0.0001; ***, P 0.0001; ****, P 0.0001; *****, P 0.002; ******, P 0.001.
(Day 56)
LCP-88/30-J8JID 2006;194:316
Systemic IgG Antibody Titers (Oral)Systemic IgG Antibody Titers (Intranasal)
Intra-peritoneal Challenge
400µL (1-2 × 105 CFU/mL 88/30 GAS) B10.BR (H-2K) mice 4-6 week old female
Prime: 30-60µg LCP-88/30-J8 
 ±10µg cholera toxin B-subunit in 20µL PBS
Boost: days 7, 14, 21, 28, 35
Intranasal Immunization
Oral Immunization
Prime: 100µg LCP-88/30-J8 
 ±10µg cholera toxin in 0.2M sodium bicarbonate
Boost: weekly intervals; 5 (with CT) or 7 (without CT)
(Day 42)
Project Aims
Lipid Core Peptide System
Advantages:
• High antibody (IgG) titers against attached peptides
• Comparable with the highly toxic adjuvant complete Freund’s adjuvant (CFA)
• Potentially safe (non-toxic) for use in humans
Disadvantages:
• Difficult to purify
• ∴not suitable for use in human clinical trials
Project Aim:
• To develop a method to enable the synthesis of highly pure, easily characterized 
analogues of the lipid core peptide system
•Techniques to be assessed:
• Solution- and solid-phase native chemical ligation
• Fragment condensation
Native Chemical Ligation (NCL)
• Formation of “Native” peptide bond
Curr Opin Biotech 1998;9:412
C-terminal Peptide
 Contains N-terminal Cysteine
N-terminal Peptide
 Contains C-terminal Thioester




 Performed at pH 7-8











i) Protecting Group (PG) Deprotection

















n-2 (n > 1)
i) Resin Cleavage
ii) Purification




















NH2Cys C12 Gly (C12)2PG
Cys C12 Gly (C12)2PG




derivatized 4% crosslinked agarose




Boc-safety-catch acid labile linker 
(CSPS pharmaceuticals, San Diego 
CA)
In oxidised (SO) form:
Stable to TFA, HF, 50% piperidine, 
Pd(0)
In reduced (S) form:
Cleaved by 50% TFA
Reducing agent:
SiCl4
Poor solubility in aqueous buffers
Problems with Solid-Phase NCL
Problems:
• Poor solubility of lipid adjuvant in aqueous buffers
• Addition of organic solvents (e.g. TFE, MeCN, DMF, dioxane)
• Solubilizes lipidic adjuvant
• Ligation does not occur
• Need excess of thioester peptide to push ligation to completion (wasteful)
• Monitoring of ligation reactions and protecting group removals difficult
• RP-HPLC provides some quantitative data
• Cleavage of product from the resin is problematic
• The resin is not completely stable to the conditions used for ligation and  
protecting group removal
Possible Solution to Solubility Issue:
• Use fragment condensation to couple lipid adjuvant to resin, then use NCL 








i) Protecting Group (PG) Deprotection

















n-2 (n > 1)
LCP Lipid Core
ii) Ligation





Cys C12 Gly (C12)2PG
Fragment Condensation:
• Solubility in DMF of lipid adjuvant 
good.
• Coupling took over 24 hours
Native Chemical Ligation:
• Only 33% complete despite using 
2eq thioester peptide
• Subsequent ligations worse
Conclusion:
• Difficult, expensive, and wasteful
• Use solution phase ligation
Solution-Phase NCL
Cys C12 Gly C12 C12 Gly NH2
Ligation
0.1M phosphate buf fer pH 7.5
MESNA
TCEP
Cys C12 Gly C12 C12 Gly NH2
LCP Lipid Core









Poor solubility of lipid adjuvant 
in aqueous buffers
Ligation does not occur
Addition of organic solvents 
(e.g. TFE, MeCN, DMF, dioxane)
• Solubilizes lipidic adjuvant
• Ligation does not occur
NCL + SDS
Minutes






























8830LCNH2 after cleavage crude +TCEP
8830LCNH2 after cleavage crude +TCEP001
Retention Time






























Ac [88/30] Lys Gly

































Ac [88/30] Lys Gly
Gly C12 C12 Gly C12 Gly Gly Gly Gly
Cys
Ac [88/30] Lys Gly





Synthesis of a Highly Pure LCP-Analogue













0.1M Phosphate Buf fer pH 7.5





0.1M Phosphate Buf fer
pH 7.5
Ac [PL1] Lys Gly C12 Gly C12 C12 Gly NH2
CysAc [88/30] Lys Gly
Cys(Acm)
ACM DEPROTECTION
i) I2, 1:1 AcOH-H2O
ii) 1M ascorbic acid
TCEP
Ac [PL1] Lys Gly C12 Gly C12 C12 Gly NH2
CysAc [88/30] Lys Gly
Cys Ac J8 Gly S Leu
O
NH2










0.1M Phosphate Buffer pH 7.6
Ac [PL1] Lys Gly C12 Gly C12 C12 Gly NH2
CysAc [88/30] Lys Gly
CysAc J8 Gly
Minutes













































PM5- J8-8830-PL1-LC PURE 0-100B30min C4vyn 214nm 1mlmin
PM5- J8-8830-PL1-LC PURE 0-100B30min C4vyn 214nm 1mlmin












































RP-HPLC: Solvent A: 0.1% TFA/H2O; Solvent B: 90% ACN/0.1% 
TFA/H2O; Flowrate: 1mL/min; Column: Vydac C4 (214TP54; 300Å; 5µm, 
4.6 x 250mm); Gradient: 0% to 100% B over 30 min; Detection: 214nm; 
tR: 18.733 min; Purity: 97.7%.
LCP-analogue 1 LCP-analogue 2
61.1% Yield
J Org Chem 2006;71(18):6846J Med Chem 2006;49(21):6364
Minutes















PM6- 8830+LC ligation pure 0-100B30min C4vyn 1mlmin 214nm
PM6- 8830+LC ligation pure 0-100B30min C4vyn 1mlmin 214nm
 +Q1: 3.874 to 10.035 min from Sample 1 (PM6- 8830+LC lig LCMS 15-90B15minCNPR0.5mlmin) of PM6- 8830+LC lig LCMS 15-90B15... Max. 2.0e5 cps.





































1569.81050.8958.6 1540.1739.6 1229.7 1338.41193.11124.7 1388.6905.4 1586.3 1796.2682.6 1814.8790.8 924.7 1537.5625.1 1672.0 1885.3700.7529.2 1660.0
C474H786N148O144S4










B: 90% ACN/0.1% TFA/H2O
Gradient: 0-100%B over 30min
Column: Vydac C4 (214TP54)



























0.1M Phosphate Buf fer pH 7.6






















Mice: 4-6 week old  ♀ B10.BR (H-2k)
Immunised at the tail base
1°: 30µg in 50µL PBS or 1:1 CFA
Boosts: 3µg in PBS (days 21, 28, 35, 42, & 49)
Conclusions
• Demonstrated a method for the synthesis of 
highly pure, multi-epitopic, self-adjuvanting
lipopeptide vaccines.
– Required the use of SDS
• May prove useful for the synthesis of multi-
epitopic vaccines against diseases caused by 
other microorganisms.
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